2020
Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience
ZEMANOVA, Milada; Robert PIRKER; Lubos PETRUZELKA; Zuzana ZBOŽÍNKOVÁ; Dragana JOVANOVIC et al.Základní údaje
Originální název
Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience
Autoři
ZEMANOVA, Milada; Robert PIRKER; Lubos PETRUZELKA; Zuzana ZBOŽÍNKOVÁ; Dragana JOVANOVIC; Mirjana RAJER; Krisztina BOGOS; Gunta PURKALNE; Vesna CERIMAN; Subhash CHAUDHARY; Igor RICHTER; Jiri KUFA; Lenka JAKUBÍKOVÁ; Marius ZEMAITIS; Marketa CERNOVSKA; Leona KOUBKOVA; Zdenka VILASOVA; Karin DIECKMANN; Attila FARKAS; Jelena SPASIC; Kateřina FRÖHLICH; Andreas TIEFENBACHER; Virag HOLLOSI; Juraj KULTAN; Iveta KOLAROVA a Jiri VOTRUBA
Vydání
RADIOLOGY AND ONCOLOGY, Ljubljana, Association of Radiology and Oncology, 2020, 1318-2099
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30204 Oncology
Stát vydavatele
Slovinsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.991
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14110/20:00115905
Organizační jednotka
Lékařská fakulta
UT WoS
EID Scopus
Klíčová slova anglicky
diagnostic procedures; multimodality treatment; non-small-cell lung cancer; stage III
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 3. 7. 2020 12:36, Mgr. Tereza Miškechová
Anotace
V originále
Background. Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the realworld setting in Central European countries to define areas for improvements. Patients and methods. This multicentre, prospective and non-interventional study collected data of patients with NSCLC stage III in a web-based registry and analysed them centrally. Results. Between March 2014 and March 2017, patients (n=583) with the following characteristics were entered: 32% females, 7% never-smokers; ECOG performance status (PS) 0, 1, 2 and 3 in 25%, 58%, 12% and 5%, respectively; 21% prior weight loss; 53% squamous carcinoma, 38% adenocarcinoma; 10% EGFR mutations. Staging procedures included chest X-ray (97% of patients), chest CT (96%), PET-CT (27%), brain imaging (20%), bronchoscopy (89%), endobronchial ultrasound (EBUS) (13%) and CT-guided biopsy (9%). Stages IIIA/IIIB were diagnosed in 55%/45% of patients, respectively. N2/N3 nodes were diagnosed in 60%/23% and pathologically confirmed in 29% of patients. Most patients (56%) were treated by combined modalities. Surgery plus chemotherapy was administered to 20%, definitive chemoradiotherapy to 34%, chemotherapy only to 26%, radiotherapy only to 12% and best supportive care (BSC) to 5% of patients. Median survival and progression-free survival times were 16.8 (15.3;18.5) and 11.2 (10.2;12.2) months, respectively. Stage IIIA, female gender, no weight loss, pathological mediastinal lymph node verification, surgery and combined modality therapy were associated with longer survival. Conclusions. The real-world study demonstrated a broad heterogeneity in the management of stage III NSCLC in Central European countries and suggested to increase the rates of PET-CT imaging, brain imaging and invasive mediastinal staging.